DRUG · Mapped RxNorm record
brigatinib
Normalized identity: brigatinibView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors
NCT02706626
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedTrial of Brigatinib After Treatment With Next-Generation ALK Inhibitors
Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Interventions
brigatinibDRUG · verified · RxNorm: brigatinib
Sponsors & collaborators
Criterium, Inc.lead sponsor
University of Colorado, Denvercollaborator
Duke Universitycollaborator
Takedacollaborator
Vanderbilt Universitycollaborator
University of Texas Southwestern Medical Centercollaborator
University of Pittsburghcollaborator
Ohio State Universitycollaborator
Georgetown Universitycollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02706626 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.